Status:
UNKNOWN
The Effect of N2O on Chronic Neuropathic Pain Patients
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Neuropathic Pain
Eligibility:
All Genders
18-65 years
Phase:
EARLY_PHASE1
Brief Summary
Important pharmacological agents for treatment of chronic neuropathic pain such as ketamine block NMDA receptors. Nitrous oxide, an inhalant agent used extensively In anesthesia, also have antagonist ...
Detailed Description
Important pharmacological agents for treatment of chronic neuropathic pain such as ketamine block NMDA receptors. Nitrous oxide, an inhalant agent used extensively In anesthesia, also have antagonist ...
Eligibility Criteria
Inclusion
- men and women at the age 18-65
- patient that suffer from chronic neuropathic pain
- VAS\>40
- DN4 score \>4
- takes pain medication on a regular basis
- Didn't get epidural injection for the pas month
- signed an informed consent form
Exclusion
- patients that suffer from chronic lung disease.
- patients with cancer
- patients with heart disease
- pregnant and lactate woman
- patients that suffer from depression
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT02246517
Start Date
September 1 2014
Last Update
September 22 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pain Medicine Unit
Tel Aviv, Israel